GERON CORP Unamortized Debt Issuance Expense
GERON CORP (GERN) had Unamortized Debt Issuance Expense of $747.00 thousand as of 2022-09-30, per its 10-Q filed 2022-11-07.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:UnamortizedDebtIssuanceExpense · last filed 2022-11-07
- 2022-09-30: Unamortized Debt Issuance Expense $747.00K.
- 2022-06-30: Unamortized Debt Issuance Expense $801.00K.
| Period end | Unamortized Debt Issuance Expense |
|---|---|
| 2022-09-30 | $747.00K 10-Q · filed 2022-11-07 |
| 2022-06-30 | $801.00K 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |